CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr | ₹4,591 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹5,484 Cr |
| Mar2024 | ₹5,246 Cr |
| Mar2023 | ₹5,033 Cr |
| Mar2022 | ₹4,913 Cr |
| Mar2021 | ₹4,591 Cr |
How is Total Current Liabilities of CIPLA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹5,484 Cr | 4.54 | |
| Mar2024 | ₹5,246 Cr | 4.22 | |
| Mar2023 | ₹5,033 Cr | 2.45 | |
| Mar2022 | ₹4,913 Cr | 7.01 | |
| Mar2021 | ₹4,591 Cr | - | |
Compare Total Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹115,887.0 Cr | -1.8% | -4.8% | -1.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹408,019.0 Cr | -3.5% | -5.4% | -3.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹168,752.0 Cr | -3.6% | 0.2% | 11.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹135,542.0 Cr | -0.5% | 5.9% | 20.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,024.7 Cr | -1.7% | -7.3% | -12.1% | Stock Analytics | |
| MANKIND PHARMA | ₹92,629.3 Cr | -0.6% | 4.7% | -19.2% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -1.8% |
-4.8% |
-1.5% |
| SENSEX | -1.9% |
-2.2% |
7.4% |
You may also like the below Video Courses